These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 38882545)

  • 1. Nano-Proteolysis Targeting Chimeras (Nano-PROTACs) in Cancer Therapy.
    Song Y; Dong QQ; Ni YK; Xu XL; Chen CX; Chen W
    Int J Nanomedicine; 2024; 19():5739-5761. PubMed ID: 38882545
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progress of proteolysis-targeting chimeras (PROTACs) delivery system in tumor treatment.
    Fan L; Tong W; Wei A; Mu X
    Int J Biol Macromol; 2024 Aug; 275(Pt 1):133680. PubMed ID: 38971291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Revolutionizing Human papillomavirus (HPV)-related cancer therapies: Unveiling the promise of Proteolysis Targeting Chimeras (PROTACs) and Proteolysis Targeting Antibodies (PROTABs) in cancer nano-vaccines.
    Mukerjee N; Maitra S; Gorai S; Ghosh A; Alexiou A; Thorat ND
    J Med Virol; 2023 Oct; 95(10):e29135. PubMed ID: 37792364
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nano Proteolysis Targeting Chimeras (PROTACs) with Anti-Hook Effect for Tumor Therapy.
    Zhang NY; Hou DY; Hu XJ; Liang JX; Wang MD; Song ZZ; Yi L; Wang ZJ; An HW; Xu W; Wang H
    Angew Chem Int Ed Engl; 2023 Sep; 62(37):e202308049. PubMed ID: 37486792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nano-PROTACs: state of the art and perspectives.
    Zhong J; Zhao R; Wang Y; Su YX; Lan X
    Nanoscale; 2024 Feb; 16(9):4378-4391. PubMed ID: 38305466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proteolysis-Targeting Chimeras (PROTACs) in Cancer Therapy: Present and Future.
    Li R; Liu M; Yang Z; Li J; Gao Y; Tan R
    Molecules; 2022 Dec; 27(24):. PubMed ID: 36557960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proteolysis targeting chimeras (PROTACs) in cancer therapy.
    Ocaña A; Pandiella A
    J Exp Clin Cancer Res; 2020 Sep; 39(1):189. PubMed ID: 32933565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted degradation of anaplastic lymphoma kinase by gold nanoparticle-based multi-headed proteolysis targeting chimeras.
    Wang Y; Han L; Liu F; Yang F; Jiang X; Sun H; Feng F; Xue J; Liu W
    Colloids Surf B Biointerfaces; 2020 Apr; 188():110795. PubMed ID: 31991291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging Strategies in Proteolysis-Targeting Chimeras (PROTACs): Highlights from 2022.
    Tamatam R; Shin D
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances and perspectives of proteolysis targeting chimeras (PROTACs) in drug discovery.
    Xi JY; Zhang RY; Chen K; Yao L; Li MQ; Jiang R; Li XY; Fan L
    Bioorg Chem; 2022 Aug; 125():105848. PubMed ID: 35533582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New-generation advanced PROTACs as potential therapeutic agents in cancer therapy.
    Wang C; Zhang Y; Chen W; Wu Y; Xing D
    Mol Cancer; 2024 May; 23(1):110. PubMed ID: 38773495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics.
    Khan S; He Y; Zhang X; Yuan Y; Pu S; Kong Q; Zheng G; Zhou D
    Oncogene; 2020 Jun; 39(26):4909-4924. PubMed ID: 32475992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PROTACs in Ovarian Cancer: Current Advancements and Future Perspectives.
    Vorderbruggen M; Velázquez-Martínez CA; Natarajan A; Karpf AR
    Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The new era of pancreatic cancer treatment: Application of nanotechnology breaking through bottlenecks.
    Luo W; Zhang T
    Cancer Lett; 2024 Jul; 594():216979. PubMed ID: 38795762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Delivering on Cell-Selective Protein Degradation Using Chemically Tailored PROTACs.
    Yao R; Luo T; Wang M
    Chembiochem; 2023 Oct; 24(19):e202300413. PubMed ID: 37496112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transforming Cancer Treatment with Nanotechnology: The Role of Berberine as a Star Natural Compound.
    Sun L; Lan J; Li Z; Zeng R; Shen Y; Zhang T; Ding Y
    Int J Nanomedicine; 2024; 19():8621-8640. PubMed ID: 39188860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proteolysis-Targeting Chimeras (PROTACs) targeting the BCR-ABL for the treatment of chronic myeloid leukemia - a patent review.
    Vicente ATS; Salvador JAR
    Expert Opin Ther Pat; 2023; 33(6):397-420. PubMed ID: 37494069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proteolysis-targeting chimera (PROTAC) delivery system: advancing protein degraders towards clinical translation.
    Chen Y; Tandon I; Heelan W; Wang Y; Tang W; Hu Q
    Chem Soc Rev; 2022 Jul; 51(13):5330-5350. PubMed ID: 35713468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies.
    He Y; Khan S; Huo Z; Lv D; Zhang X; Liu X; Yuan Y; Hromas R; Xu M; Zheng G; Zhou D
    J Hematol Oncol; 2020 Jul; 13(1):103. PubMed ID: 32718354
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PROTACs: Promising approach for anticancer therapy.
    Kaur SD; Bedi N; Kumar D; Kapoor DN
    Cancer Lett; 2023 Mar; 556():216065. PubMed ID: 36642326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.